Shilpa CDMO peptide investment puts a first commercial line in Raichur by December

Shilpa CDMO said on 3 November 2026 that it will put $50 million, in phases, into peptide manufacturing at its Unit-I campus in Raichur, Karnataka. The Shilpa CDMO peptide investment begins with a first commercial production line due to open in December 2026, followed by larger synthesis reactors over the next few years. The company linked the plan to demand for GLP-1 medicines and for more complex peptides used in cancer and rare disease research. It named no customers, molecules or committed volumes.

Inside the Raichur peptide plant plan

According to the company release as reported by BioPharm International, the new commercial line will sit beside three lines that already make peptides for clinical trials, and commercial supply is set to ramp up through 2027. The line pairs 500 litre and 1,000 litre reactors in a single block and is rated for up to one metric ton of peptide a year. Purification, a step other contract makers have described as a bottleneck in peptide scale up, runs through two 2 metre dynamic axial compression columns feeding a preparative HPLC system sized at 10,000 litres per hour. Downstream, the line adds nanofiltration at 1,000 litres per hour and a 1,000 litre freeze dryer, which turns purified peptide solution into a dry powder.

The Shilpa CDMO peptide investment as a whole adds 10 kL of solid phase reactor volume, with later phases bringing 2 kL, 3 kL and 5 kL reactors. The finished Raichur peptide plant would run six parallel current good manufacturing practice lines, so several client programmes can move at once, and one line is reserved for cytotoxic peptides made by solid phase synthesis. Indian Pharma Post reports that the peptide unit sits inside a 34 acre campus and is built for active ingredients, linkers, peptide drug conjugates and highly potent compounds in containment bands OEB 1 to 6. A central distributed control system with process analytical technology and UV monitoring will run the line, and the company said design of experiments and simulation will set operating ranges before scale up.

SPPS reactor capacity and the choice of route

Solid phase peptide synthesis, or SPPS, builds a peptide one amino acid at a time on resin beads, washing away spare reagents after each step. Adding SPPS reactor capacity in larger vessels raises batch size, but long chains also build up impurities that purification must later remove. Shilpa says its platform also runs liquid phase synthesis and hybrid routes, in which shorter fragments are made separately and then joined. It lists linear, cyclic and branched peptides, unnatural and D-amino acids, lipidation, conjugation and radioligand peptides among its skills. Lipidation is the kind of fatty side chain that helps semaglutide work as a weekly injection, although Shilpa has not said it will make that molecule or any other named drug.

Kalita said in the release that "considering commercial scale from the outset helps customers avoid reaching late-stage development with a process that is no longer technically or economically viable."

Dipak Kalita, senior vice president of CDMO services at Shilpa CDMO, said the company starts from the molecule and its likely commercial needs before it chooses solid phase, liquid phase or a hybrid route. He said longer peptides can shift to "a hybrid fragment-based route as volumes grow." Kalita said in the release that "considering commercial scale from the outset helps customers avoid reaching late-stage development with a process that is no longer technically or economically viable." Indian makers know what a scale up problem costs: this site reported that Dr Reddy's semaglutide pen supply stopped in July after a scaled up ingredient batch produced an impurity in the finished drug. Shilpa has not published yields, purity data or inspection results for its Raichur peptide lines.

Why Shilpa looks beyond GLP 1 demand

"Peptides are becoming one of the most important areas of pharmaceutical development, but the opportunity goes well beyond current GLP-1 demand," chief executive Keshav Bhutada said in the release. He pointed to innovator pipelines in oncology and rare diseases, which he said produce more sophisticated molecules and conjugates that need deeper skill in route design, synthesis, purification and scale up. "We are investing for where the peptide market is going next," he added. The Shilpa CDMO peptide investment therefore reads as a bet on two kinds of client: GLP-1 peptide manufacturing, where volume matters most, and smaller, harder programmes in cancer and rare disease. The company did not say how the new capacity will be split between them.

The people behind the plan are also described only in company terms. Shilpa said its peptide business already employs over 100 people in science and production roles, and that more than 50 of them sit in research and development. The trade site adds 45 chemists across production and purification, backed by more than 350 PhDs in the wider Shilpa group. Shilpa CDMO itself is new as a brand. It was launched at CPHI Milan in October 2026 as a complex molecule business, and Indian Pharma Post describes it as a business unit of Shilpa Medicare Limited. At that launch the company said it would later give details of commercial scale peptide work, and this announcement is that follow up. The cytotoxic line and radioligand work point to conjugates rather than only obesity drugs.

An Indian peptide CDMO in a global build out

Shilpa joins a wider build out by contract makers. At home, Laurus Labs agreed to buy 52% of a peptide resin maker and says its new Vizag peptide plant is running. Abroad, Samsung Biologics reported on 2 November that holders of 97.66% of PolyPeptide Group shares had tendered in its offer for the peptide ingredient contract maker. As this desk has reported, settlement of that deal still waits on clearances in several markets, India among them. In 2025, SK pharmteco put $6.1 million into kilo scale SPPS and purification in Rancho Cordova, California. For an Indian peptide CDMO, the pitch to foreign buyers rests on scale, cost and a clean inspection record, none of which this release yet proves.

Several gaps remain in the Shilpa CDMO peptide investment. Most of the reactor volume will arrive over the next few years, and Shilpa gave no date for each reactor. It named no customers, programmes or committed volumes, so it is not clear how much of the first line is already booked. Its claim that the expanded site will be one of India's largest multi-ton peptide operations is the company's own description, not an independent count. The one metric ton figure is the rated yearly ceiling of the first line, not a measured output. Readers should watch for the December opening at Raichur, any named client or supply contract, and the first regulatory inspection of the commercial line by Indian or foreign authorities, for which no date has been reported.

Conclusion

The Shilpa CDMO peptide investment gives India another contract maker with a dated commercial peptide line, due in December 2026, and a plan for 10 kL of new solid phase reactors. What it does not yet give is evidence: no clients, no batch data and no timetable beyond the first line. The next useful signals are the line opening, the first named customer and the first inspection.